← All trials
NCT07027748
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 27, 2025
- Primary completion
- Dec 1, 2026
- Completion date
- Dec 1, 2027
- First posted
- Jun 18, 2025
- Last posted
- Jul 14, 2025
- Enrollment
- 18
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Harvard UniversityLead sponsor
- Harvard UniversityOfficial
- Harvard UniversitySponsor investigator
- Y-Mabs, IncCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.